Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM-OX in Hepatocellular Carcinoma
NCT00250822Phase 2Completed
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Oct 2005
- Primary completion
- Jul 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in hepatocellular carcinoma (HCC), sponsored by New Mexico Cancer Research Alliance. Primary endpoint: Response Rate (CR + PR rate). Started Oct 2005; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00250822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250822.